Azenta, Inc. · NASDAQ:AZTA
Azenta — Investor Day (March 2024)
66 slides from Azenta's investor day presentation, Mar 14, 2024
Slide 1: Transforming our Platform for Sustained Profitable Growth
Transforming our Platform for Sustained Profitable Growth Investor Day March 14, 2024 © 2024 Azenta, Inc. All rights reserved
Slide 2: Welcome
Welcome Sara Silverman Head of Investor Relations Azenta Life Sciences | Proprietary and confidential. 2
Slide 3: Safe Harbor Statement
Safe Harbor Statement “Safe Harbor” Statement under the U.S. Private Securities Litigation Reform Act of 1995; certain matters in this presentation, including forecasts of future demand and future Company performance, are forward-looking statements that are subject to risks and uncertainties that co
Slide 4: Investor Day Agenda
IN V E STOR DAY AG E N DA Transforming our Platform for Sustained Profitable Growth Topic Speaker Introduction Sara Silverman, Head of IR Strategic Overview & Vision Steve Schwartz, President & CEO Q&A Break Financial Review Herman Cueto, EVP & CFO Q&A and Conclude Lunch & Departure © 2024 Azenta, I
Slide 5: Azenta – A Leading, Differentiated Life Sciences Company
Azenta – A Leading, Differentiated Life Sciences Company CLICK TO PLAY VIDEO © 2024 Azenta, Inc. All rights reserved 5
Slide 6: Transforming our Platform for Sustained Profitable Growth
Transforming our Platform for Sustained Profitable Growth Steve Schwartz President and Chief Executive Officer Azenta Life Sciences | Proprietary and confidential. 6
Slide 7: Our Purpose: Enabling Breakthroughs Faster
OUR PURPOSE Enabling Breakthroughs Faster © 2024 Azenta, Inc. All rights reserved 7
Slide 8: Our Path to Sustainable, Profitable Growth
K E Y ME SSAG E S FOR T HE DAY Our Path to Sustainable, Profitable Growth 1 2 3 Strong positions in Investing in Positioned to large, attractive transformation for outperform in any markets scale and profitability market environment Long-term opportunity enabled by near-term transformation © 2024 Az
Slide 9: Agenda
AGENDA Transforming our Platform for Sustained Profitable Growth High value, differentiated platform Uniquely positioned to outperform end market growth Investing in multiple growth drivers © 2024 Azenta, Inc. All rights reserved 9
Slide 10: A Well-Established Global Life Sciences Leader
AT A G L A N C E A Well-Established Global Life Sciences Leader FY’23 Revenue by Segment Revenue by Region Key Metrics ~13,000 al 17% 54% 20% Customers e dic M u NA Europe M lti 20 of 20 B om Top Pharma/Biotech 8% ics 3 7 China $665M >150 % Samp Countries le 1 in 3 employees is M na a ge a scientist
Slide 11: Highly Differentiated Sample Management Portfolio
Highly Differentiated Sample Management Portfolio Provides Comprehensive End-to-End Solutions Find Format Store / Manage Measure Inform Sample Consumables Storage, Genomics Data and Sourcing & Instruments Automation and Analytical Informatics and Logistics Services Sample / Drug Patient Development
Slide 12: Our Customers are at the Forefront of Scientific Breakthroughs
Our Customers are at the Forefront of Scientific Breakthroughs from Discovery to Delivery 27,500 20 of 20 33 of 50 Top pharma / biotech 33 Citations in served by Azenta Top customers purchase 13,000+ scientific journals across multiple business lines Nobel laureate labs use Azenta Total customers se
Slide 13: Agenda
AGENDA Transforming our Platform for Sustained Profitable Growth High value, differentiated platform Uniquely positioned to outperform end market growth Investing in multiple growth drivers © 2024 Azenta, Inc. All rights reserved 13
Slide 14: Leveraging Competitive Advantages to Capture Market Share
Leveraging Competitive Advantages to Capture Market Share 1 Unique portfolio with differentiated offerings 2 Cutting edge technologies wherever we operate 3 Best-in-class team with > 400 advanced degree scientists 4 Company size enables us to be nimble The Trusted Partner in Sample Management and An
Slide 15: Portfolio Positioned to Capitalize on Market Trends
Portfolio Positioned to Capitalize on Market Trends Novel Modalities Driving Demand for Cell & Gene Demand for Sample Products Therapy, the Automated & Services Quality Sample Next Frontier Temperature Collections are Trend Toward Control Essential Outsourcing R&D >20% ~2K >45% 2X Growth expected in
Slide 16: ~$11B TAM Provides Significant Opportunity
~$11B TAM Provides Significant Opportunity Total Addressable Market The Near-Term Opportunity B Medical / Sample ~$11B • Large, diverse market Sourcing $1B Sample Market Management $7B Solutions <10% • Small share in a large market Market Share $3B Multiomics Low-Single • Market growth rate FY’23-26
Slide 17: Agenda
AGENDA Transforming our Platform for Sustained Profitable Growth High value, differentiated platform Uniquely positioned to outperform end market growth Investing in multiple growth drivers © 2024 Azenta, Inc. All rights reserved 17
Slide 18: Multiple Growth Drivers for Near and Longer-Term Growth
Multiple Growth Drivers for Near and Longer-Term Growth Segment % of FY’23 Revenue Key Growth Drivers Sample • Capitalizing on wave of samples Management Solutions 46% • Conversion to automation • New scientific service offerings Multiomics 37% • Geographic expansion • Aligned with Azenta B Medical
Slide 19: Multiple Growth Drivers for Near and Longer-Term Growth
Multiple Growth Drivers for Near and Longer-Term Growth Segment % of FY’23 Revenue Key Growth Drivers Sample • Capitalizing on wave of samples Management Solutions 46% • Conversion to automation • New scientific service offerings Multiomics 37% • Geographic expansion • Aligned with Azenta B Medical
Slide 20: Meaningful Discoveries Start with High Quality Samples
S A M P L E S A R E AT T H E C E N T E R O F E V E RY T H I N G W E D O Meaningful Discoveries in Life Sciences Start with High Quality Samples. Billions of them… ~50% or ~1.3B of Samples Generated Our Opportunity Each Year Require Ultracold Storage Samples Generated per year by Storage Temperature
Slide 21: Automated Store Systems Applications Continue to Expand
SAMPLE MANAGEMENT SOLUTIONS Automated Store Systems Applications Continue to Expand into New Areas Drivers Stores Revenue Growth (FY’20-23) • Strong competitive moat built over ~$70M the past decade of innovation 24% CAGR New >100% investments Vectors CAGR • Cryo for Cell and Gene Therapy is a uniqu
Slide 22: Customers Increasingly Look to Azenta for Outsourced Repository Services
SAMPLE MANAGEMENT SOLUTIONS Customers Increasingly Look to Azenta for Outsourced Sample Repository Services Drivers Samples in Storage at Azenta Millions • Sample collection size and complexity are 60 driving sustained growth • Much more than a storage repository as 50 we now handle ~1 million sampl
Slide 23: BioArc Ultra is the Transformative Solution
SAMPLE MANAGEMENT SOLUTIONS BioArc Ultra is the Transformative Solution to Address the Demand Wave © 2024 Azenta, Inc. All rights reserved 23
Slide 24: Automation Meaningfully Simplifies Operations
Automation Meaningfully Simplifies Operations BioArc Ultra Manual freezer 3 BioArc Ultras ~ 4,800 Sq. Ft 450 ft 80 ft 235 ft 60 ft • Significant footprint reduction • >75% reduction in energy consumption, C02 emissions • Dramatic reduction in cycle time • Significant cost efficiency Note: Hypothetic
Slide 25: Multiple Growth Drivers for Near and Longer-Term Growth
Multiple Growth Drivers for Near and Longer-Term Growth Segment % of FY’23 Revenue Key Growth Drivers Sample • Capitalizing on wave of samples Management Solutions 46% • Conversion to automation • New scientific service offerings Multiomics 37% • Geographic expansion • Aligned with Azenta B Medical
Slide 26: New Areas Beginning to Contribute to Growth
M U LT I O M I C S New Areas Beginning to Contribute to Growth on Top of a Healthy Base Business Multiomics Revenue ($M) ~5% CAGR $248 >20% CAGR from $225 New Growth New Growth Areas: Areas • Proteomics • Single cell Synthesis • Clinical services Next- ~3% CAGR from Generation Sequencing Base Busine
Slide 27: We are Investing to Stay in Front of Our Opportunities
M U LT I O M I C S We are Investing to Stay in Front of Our Opportunities Example: Investing to Remain at the Forefront New Vectors/Capacity Additions of NGS Technology Transformation NGS Data Generated by Installed Equipment Type → Investments for sustained leadership in new scientific areas HiSeq
Slide 28: Multiple Growth Drivers for Near and Longer-Term Growth
Multiple Growth Drivers for Near and Longer-Term Growth Segment % of FY’23 Revenue Key Growth Drivers Sample • Capitalizing on wave of samples Management Solutions 46% • Conversion to automation • New scientific service offerings Multiomics 37% • Geographic expansion • Aligned with Azenta B Medical
Slide 29: Near Term Repositioning, Enhancing Profitability
B MEDICAL Near Term Repositioning, Enhancing Profitability B Medical -- Today B Medical – Go Forward State • >80% of revenue and >90% of gross profit is from • Focus portfolio exclusively on VCC Vaccine Cold Chain (“VCC”) ‒ Exit non-VCC product lines • The remainder is non-VCC (i.e. Medical Refriger
Slide 30: Upside Opportunities from Sample Acquisition Enabled by B Medical
B MEDICAL Significant Upside Opportunities from Sample Acquisition Enabled by B Medical Platform The Opportunity B Medical Platform Reach in Africa • Human biological samples from Africa have tremendous value for discovery because of genetic diversity • Strong interest from Ministries of Health and
Slide 31: Case Study with 20+ Year Global Big Pharma
CUSTOMER CASE STUDY Case Study with 20+ Year Global Big Pharma Demonstrates Growth in Services Used Revenue • Reached >5M samples stored at Azenta 3X • Added 3 large automated stores • Installed 100M+ sample capacity at HQ FY'20 FY'21 FY'22 FY'23 2023 • Expanded GENEWIZ services • Preferred provider
Slide 32: 3-Year Target Revenue Model Summary & Growth Drivers
3-Year Target Revenue Model Summary & Growth Drivers Sample Management Solutions (“SMS”) Multiomics B Medical Pro Forma1 LSD Organic growth % HSD Organic growth % MSD Organic growth % Pro Forma Revenue2 CAGR FY’23-26 • Market conversion to • Continued growth in • Exiting non-VCC product 5-8% automat
Slide 33: 3-Year Target Model Summary
3-Year Target Model Summary Pro Forma Adj. EBITDA Margin Free Cash Flow EPS Growth Revenue Growth1 5-8% 15-17% $100M+ >45% CAGR FY’23-26 in FY’26 Cumulative CAGR FY’23-262 FY’24-26 FY26: $0.75 - $1.20 1: Pro forma revenue excludes $16M of revenue from product lines that we are winding down starting
Slide 34: FY'24-26 is a Critical Period on Our Journey
FY’24-26 is a Critical Period on Our Journey to Longer Term Growth and Profitability 2021 to 2023 2024 to 2026 2027+ Launch Azenta Execution Focused Continued Profitable Growth • Created a unique, standalone • Investing in defensible growth • Accelerate growth life sciences company • Building the fo
Slide 35: Q&A
Q&A Azenta Life Sciences | Proprietary and confidential. 35
Slide 36: 10 Minute Break
10 Minute Break Azenta Life Sciences | Proprietary and confidential. 36
Slide 37: Driving Performance: Our Roadmap for Success
Driving Performance: Our Roadmap for Success Herman Cueto Chief Financial Officer Azenta Life Sciences | Proprietary and confidential. 37
Slide 38: Agenda
AGENDA Driving Performance: Our Roadmap for Success Planning for sustained profitable growth Transformation for scale and growth – Ascend 2026 Disciplined capital allocation strategy How we will measure success – roadmap to 2026 © 2024 Azenta, Inc. All rights reserved 38
Slide 39: A Look Back on Recent Results
A Look Back on Recent Results. Initiatives Underway to Drive Improved Performance Revenue Adjusted EBITDA Margin* ($M) (%) 5-8% growth $696-718M 11.3% $665 $555 ~300bps improvement 4.6% FY'22 FY'23 FY'24E FY'22 FY'23 FY'24E Note: FY’24E based on the midpoint of guidance as previously disclosed on 11
Slide 40: Early Evidence Our Initiatives Are Working
Early Evidence Our Initiatives Are Working >300 bps of adj. EBITDA margin expansion 1H to 2H’23 Completed cost actions announced in FY’23 for $28M in annual savings Strong Q1’24 margin and cash flow performance On track for ~300 bps of adj. EBITDA margin expansion FY’23 to FY’24E © 2024 Azenta, Inc.
Slide 41: Driving Operational Excellence
Driving Operational Excellence: Building the Foundation For Scale and Growth Our Playbook Deliver Measurable Results • Reduce complexity • Establishing transformation management office with executive leaders • Rebuild system infrastructure • Commitment to new long-term model • Optimize, create stand
Slide 42: Agenda
AGENDA Driving Performance: Our Roadmap for Success Planning for sustained profitable growth Transformation for scale and growth – Ascend 2026 Disciplined capital allocation strategy How we will measure success – roadmap to 2026 © 2024 Azenta, Inc. All rights reserved 42
Slide 43: Launched Transformational Program, Ascend 2026
Launched Transformational Program, Ascend 2026: Targeting $30-40M in Cost Actions by FY’26 The Opportunity The Solution The Goal • Rapid growth last 10 years • Streamlining and – 15+ acquisitions simplifying under • Accumulated layers of Transformation Deliver cost reduction Management Office comple
Slide 44: Ascend 2026 Business Transformation Strategy – Situation Today
Ascend 2026 Business Transformation Strategy – Situation Today Today Future IT Systems 13 Physical Sites 45 Legal Entities 39 “Ascend’26” Transformation Countries 13 Strategy SG&A % of Sales1 41% Adj. EBITDA Margin1,2 4.6% 1: As of FY 2023 2: Non-GAAP financial measures – see reconciliation tables i
Slide 45: Project Ascend 2026: Key Identified Programs
Project Ascend 2026: Key Identified Programs Program Goals Est. savings 1. Site Rationalization • Reduce from 45 sites in 13 countries to ~25 sites by FY26 • Simplify legal entity structure $10M to $15M 2. Portfolio Optimization • Exit non-core, sub-scale, sub-profitable product lines • Invest in st
Slide 46: Case Study: Finance Department Simplification
Case Study: Finance Department Simplification Situation Results Current State: Cost of Finance Cost of Finance department is ~5% of sales vs benchmark <2% Root Cause: 1-2pts of improvement Complexity from 15+ acquisitions over the past decade ~5% of sales Our Solution: ~3-4% Site rationalizati
Slide 47: Ascend'26 – What Success Will Look Like
Ascend’26 Business Transformation Strategy – What Success Will Look Like Sept. 30, 2026 Today Today Sept. 30, 2026 IT Systems 13 6 Physical Sites 45 <25 Legal Entities 39 <25 SG&A % of Sales1 41% ~Mid-30%s Adj. EBITDA Margin1,2 4.6% 15-17% 1: As of FY 2023 2: Non-GAAP financial measure – see reconci
Slide 48: What to Expect: Timing of Cost Savings
What to Expect: Timing of Cost Savings Annual Savings by Year Profit Improvement Beyond FY'26 ~1,100bps • Broad scale EBITDA Margin FY’25-26 automation in the factories and the Expansion • Phase II initiatives function FY’23-261 FY’24 announced in FY23 • Future wave of • Ascend 2026 Ascend benefits
Slide 49: Agenda
AGENDA Driving Performance: Our Roadmap for Success Planning for sustained profitable growth Transformation for scale and growth – Ascend 2026 Disciplined capital allocation strategy How we will measure success – roadmap to 2026 © 2024 Azenta, Inc. All rights reserved 49
Slide 50: $1.5B Capital Deployed Since Becoming Azenta in 2022
$1.5B Capital Deployed Since Becoming Azenta in 2022 Over 2 years, $1.5B of capital deployed Return Cash to Organic Investment Acquisitions Shareholders 12% 34% 54% • R&D ~5% of revenue • B Medical • $1B share repurchases • CAPEX investments • Barkey for growth • Ziath © 2024 Azenta, Inc. All rights
Slide 51: Going Forward: Consistent Capital Deployment
Going Forward: Consistent Capital Deployment Toward Value Creating Initiatives Invest • R&D ~5% of revenue in the Core • Capital expenditures 6-8% of revenue Free Cash Flow • Strategic, tuck-in M&A Cumulative $100M+ FY’24-26 Share Repurchases • $500M planned for FY’24 Exit FY24 in a strong balance s
Slide 52: Agenda
AGENDA Driving Performance: Our Roadmap for Success Planning for sustained profitable growth Transformation for scale and growth – Ascend 2026 Disciplined capital allocation strategy How we will measure success – roadmap to 2026 © 2024 Azenta, Inc. All rights reserved 52
Slide 53: 3-Year Target Revenue Model Summary & Growth Drivers
3-Year Target Revenue Model Summary & Growth Drivers Sample Management Solutions (“SMS”) Multiomics B Medical Pro Forma1 LSD Organic growth % HSD Organic growth % MSD Organic growth % Pro Forma Revenue2 CAGR FY’23-26 • Market conversion to • Continued growth in • Exiting non-VCC product 5-8% automat
Slide 54: 3-Year Target Model Summary
3-Year Target Model Summary Pro Forma Adj. EBITDA Margin Free Cash Flow EPS Growth Revenue Growth1 5-8% 15-17% $100M+ >45% CAGR FY’23-26 in FY’26 Cumulative CAGR FY’23-262 FY’24-26 FY26: $0.75 - $1.20 1: Pro forma revenue excludes $16M of revenue from product lines that we are winding down starting
Slide 55: Programs Identified to Deliver 300-400 bps Margin Improvement
Programs Identified to Deliver 300-400 bps Adj. EBITDA Margin Improvement Per Year FY’24-26 & Long-Term Margins >20% 20%+ 15-17% io n an s exp rg in m a 4.6% 0 b ps ,10 ~1 Note: FY2023 adj. EBITDA is a non-GAAP financial measure – see reconciliation tables in appendix. © 2024 Azenta, Inc. All rights
Slide 56: Underlying Modeling Assumptions
Underlying Modeling Assumptions Item FY’24 FY’25 & 26 Interest Income $27M to $29M ~$12-16 million per year Tax Rate 33% to 37% 27% to 29% Average Share Count ~52 million ~ 47.5 million Debt No Debt No Debt Note: FY’24 guidance as previously disclosed on 11/13/23 and 2/7/24. © 2024 Azenta, Inc. All
Slide 57: Executing Clear Strategy for Growth
IN SUMMARY Executing Clear Strategy for Growth 1. Strong, differentiated portfolio in attractive end markets 2. Transforming Azenta for scalable, profitable growth 3. Initiatives underway to improve margins 4. Continued disciplined capital allocation 5. Clear path forward with measurable milestones
Slide 58: Q&A
Q&A Azenta Life Sciences | Proprietary and confidential. 58
Slide 59: Our Path to Sustainable, Profitable Growth
IN SUMMARY Our Path to Sustainable, Profitable Growth 1 2 3 Strong positions in Investing in Positioned to large, attractive transformation for outperform in any markets scale and profitability market environment Long-Term Opportunity Enabled By Near-Term Transformation © 2024 Azenta, Inc. All right
Slide 60: Feedback on Today's Event
Feedback on Today’s Event Thank you for joining us for our 2024 Investor Day. We hope you found it informative. Your feedback is important to us, so we would appreciate it if you could fill out a quick survey - it should take only 2-3 minutes. The answers are all anonymous. This survey will be onlin
Slide 61: Appendix
Appendix © 2024 Azenta, Inc. All rights reserved 61
Slide 62: New Three Segment Structure Starting FY'24
New Three Segment Structure Starting FY’24 37% 1. Multiomics Gene 46% Next Generation Sequencing Synthesis ▪ Experience processing over 100 sample & Other Sample 2. Sample Management Solutions types, including proteomics solutions 13% Repository Sanger Solutions Sample Repository Solutions Sanger Se
Slide 63: Broad Exposure to End Markets
Broad Exposure to End Markets Revenue Breakdown by End Market (FY’23) 45% 9% Pharma/ Biotech Other 15% Emerging Markets 15% Medical/ 16% Government / Academic Non-Profit © 2024 Azenta, Inc. All rights reserved 63
Slide 64: 10+ Years Building a Leading-Edge Life Sciences Company
10+ Years Building a Leading-Edge Life Sciences Company 2011-2012 2013-2014 2015-2016 2017-2018 2019-2020 2021 2022-2023 •BioCision 2 •GENEWIZ •Abeyance •Barkey •RTS •Matrical •FluidX •PBMMI •RURO •B Medical •Nexus •BioCision 1 •BioStorage •FreezerPro •Trans-Hit Azenta Life •Ziath Technologies •4tit
Slide 65: Portfolio Offering Examples
Portfolio Offering Examples Automated Stores Sample Repository Solutions B Medical Systems SampleStoreTM BioStoreTM BioStoreTM III Cryo Consumables & Instruments Genomic Services Sanger Gene Next Generation Sequencing Synthesis Sequencing © 2024 Azenta, Inc. All rights reserved 65
Slide 66: Net Income to Adjusted EBITDA Reconciliation
Net Income to Adjusted EBITDA Reconciliation Continuing Operations $ millions FY22 FY23 Net income 2,132.9 (14.3) (Income) Loss from discontinued operations, net of tax (2,144.1) 1.4 Net income (Loss) from continuing operations (11.3) (12.9) Adjustments: Interest income (20.3) (43.7) Interest expens